Basic and clinical aspects of the alpha1-antitrypsin

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• Alpha1-antitrypsin (AAT) deficiency, identified in 1963, is a genetic condition affecting a major serum alpha-globulin.
• This deficiency is familial and strongly associated with chronic lung diseases, typically manifesting in early adulthood.
• It is also linked to familial infantile cirrhosis and combined childhood lung and liver disease.

Purpose of the Study:

• To review the basic and clinical features of alpha1-antitrypsin.
• To highlight the importance of alpha1-antitrypsin in pediatric medicine.
• To discuss its role in differential diagnosis for pediatric conditions.

Main Methods:

• Literature review of early descriptions and subsequent research on alpha1-antitrypsin deficiency.
• Analysis of clinical associations with lung and liver diseases.
• Examination of the protein's function and diagnostic relevance in pediatrics.

Main Results:

• Severe alpha1-antitrypsin deficiency is a recognized genetic disorder with significant pulmonary and hepatic manifestations.
• It is a key consideration in the differential diagnosis of chronic childhood pulmonary disease and neonatal obstructive jaundice.
• Low AAT levels are observed in respiratory distress syndrome, while elevated levels can occur in various clinical scenarios.

Conclusions:

• Alpha1-antitrypsin plays a critical role in protecting tissues from enzymatic damage.
• Understanding AAT deficiency is essential for pediatricians managing chronic lung and liver conditions.
• This protein's levels and function have broad clinical implications across different age groups and diseases.